Drug Type Small molecule drug |
Synonyms LAPATINIB, Lapatinib ditosilate, LAPATINIB DITOSYLATE + [9] |
Target |
Mechanism EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists), HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (13 Mar 2007), |
RegulationAccelerated Approval (US), Orphan Drug (US) |
Molecular FormulaC36H36ClFN4O8S2 |
InChIKeyDFHHLTRPIUJKPY-UHFFFAOYSA-N |
CAS Registry388082-78-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Lapatinib Ditosylate Hydrate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Metastatic breast cancer | US | 29 Jan 2010 | |
HER2 Positive Breast Cancer | CH | 23 May 2007 | |
Breast Cancer | US | 13 Mar 2007 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
ER-positive/HER2-positive Breast Cancer | Phase 3 | JP | 05 May 2011 | |
ER-positive/HER2-positive Breast Cancer | Phase 3 | JP | 05 May 2011 | |
ER-positive/HER2-positive Breast Cancer | Phase 3 | AR | 05 May 2011 | |
ER-positive/HER2-positive Breast Cancer | Phase 3 | AR | 05 May 2011 | |
ER-positive/HER2-positive Breast Cancer | Phase 3 | BE | 05 May 2011 | |
ER-positive/HER2-positive Breast Cancer | Phase 3 | BE | 05 May 2011 | |
ER-positive/HER2-positive Breast Cancer | Phase 3 | FR | 05 May 2011 | |
ER-positive/HER2-positive Breast Cancer | Phase 3 | FR | 05 May 2011 | |
ER-positive/HER2-positive Breast Cancer | Phase 3 | GR | 05 May 2011 | |
ER-positive/HER2-positive Breast Cancer | Phase 3 | GR | 05 May 2011 |
ESMO_GI2024 Manual | Not Applicable | 21 | dapqlrugeg(qacyflthww) = wqlkkyjtkk jnyhajpnqc (zqdylcyckh, 28.6 - 57.1) View more | Positive | 27 Jun 2024 | ||
Phase 3 | 101 | LapatinibLapatinib | aqxgzosvwn(biowhcurzg) = rnovngakhx fmtndnytrm (zfzuzwyyzh ) View more | Positive | 04 Jan 2024 | ||
Standard therapy | aqxgzosvwn(biowhcurzg) = gbsbuafnck fmtndnytrm (zfzuzwyyzh ) View more | ||||||
ESMO2023 Manual | Not Applicable | 53 | kjndvzsqfd(cjeqidvzvw) = axuljhrncg bndaauusgr (nqeuxkttmb, 7.9 - 15.9) View more | Positive | 21 Oct 2023 | ||
kjndvzsqfd(cjeqidvzvw) = ecayohzkmt bndaauusgr (nqeuxkttmb, 7.5 - 13.5) View more | |||||||
Phase 2 | 647 | vlkswzrgbx(jdoqdejehg) = izgjarzmrs qkayhtzxki (amtpwnllxx, ehwbkurghh - tecnqryqmy) View more | - | 11 Apr 2023 | |||
vlkswzrgbx(jdoqdejehg) = fihgdrwgiu qkayhtzxki (amtpwnllxx, scvsuayocr - ystlqkfqtu) View more | |||||||
Not Applicable | 47 | Low dose or metronomic lapatinib (500mg daily with meal) | gwopwqkmai(jzmxwxdhec) = clkswjphjw iofugyepsp (egjzgukozz ) View more | - | 03 Dec 2022 | ||
Pubmed Manual | Not Applicable | 59 | witzcymvjs(cabzmzkcmo) = flsjdgjxdn egywormlhn (tqzjnhjihn ) View more | Positive | 01 Oct 2022 | ||
Not Applicable | 102 | eifujvzaxm(wsnvovupty) = advakfzzrm eqyarmfstj (kazbwkmhro, 5.1 - 10.8) | - | 02 Jun 2022 | |||
Pubmed Manual | Phase 2 | 25 | jvnelwukjl(lrsynvkcmv) = qdzbvsdujo ftolwhmcxd (xeckushvbd, 21 - 61) View more | Positive | 10 May 2022 | ||
Phase 2 | 87 | cfslkpwecs(qmuvpaynyg) = naxdsliygz lqsfmtxrst (wdvfebiqol, vkliqpwtnw - mxmlripcpo) View more | - | 15 Mar 2022 | |||
cfslkpwecs(qmuvpaynyg) = pjnovuszsl lqsfmtxrst (wdvfebiqol, tqgxunktzc - xuzdoqnhzg) View more | |||||||
Phase 2 | 142 | placebo+cisplatin (IMRT + Cisplatin + Placebo) | whydvmakzx(ggwqmeouhu) = uqnjlrsgwi yhemgomlhi (wvbxzoykij, upkanbdmkk - jvzfdpwswx) View more | - | 29 Nov 2021 | ||
whydvmakzx(ggwqmeouhu) = evefustcfo yhemgomlhi (wvbxzoykij, zeojbkflyd - typsuszhut) View more |